Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Hanson Hanqing ZhaoLauren E HowardAmanda M De HoedtMartha K TerrisChristopher L AmlingChristopher J KaneMatthew R CooperbergWilliam J AronsonZachary KlaassenThomas J PolascikAdriana C VidalStephen J FreedlandPublished in: The Prostate (2021)
Despite the common use of concomitant therapy in this real-world study, there was no difference in OS among mCRPC patients. A nonsignificant increased SRE risk was observed. Further work needs to evaluate the optimal sequence, timing, and safety of combination therapies.